The University of Florida, Division of Sponsored Research, received a $371,905 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research on the role of angiopoietin-like 4 (ANGPTL4) in clear cell renal cell carcinoma (CCRCC). The key objectives are to: 1) define the role of ANGPTL4 in the CCRCC tumor microenvironment, including its effects on tumor progression, metastasis, and vascularization; 2) test the efficacy of combining anti-ANGPTL4 antibodies with immune checkpoint inhibitors in CCRCC mouse models; and 3) determine the cancer cell intrinsic functions of ANGPTL4 related to lipid metabolism regulation. This 5-year research project aims to establish the mechanistic role of ANGPTL4 in CCRCC pathophysiology and evaluate its potential as a therapeutic target in combination with immunotherapies.
Generated 2/25/25, 2:57 AM